Latest Cormorant Asset Management, LP Stock Portfolio
Cormorant Asset Management, LP Performance:
2025 Q4: 38.71%YTD: 40.04%2024: -1.93%
Performance for 2025 Q4 is 38.71%, and YTD is 40.04%, and 2024 is -1.93%.
About Cormorant Asset Management, LP and 13F Hedge Fund Stock Holdings
Cormorant Asset Management, LP is a hedge fund based in Boston, MA. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Cormorant Asset Management, LP reported an equity portfolio of $2.2 Billions as of 31 Dec, 2025.
The top stock holdings of Cormorant Asset Management, LP are PRAX, , . The fund has invested 12.9% of it's portfolio in PRAXIS PRECISION MEDICINES I and 10.3% of portfolio in BRIDGEBIO ONCOLOGY THERAPEUT.
The fund managers got completely rid off ARCELLX INC (ACLX), CG ONCOLOGY INC and AVIDITY BIOSCIENCES INC (RNA) stocks. They significantly reduced their stock positions in NEWAMSTERDAM PHARMA COMPANY (NAMS), INSMED INC (INSM) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). Cormorant Asset Management, LP opened new stock positions in OLEMA PHARMACEUTICALS INC (OLMA), ASCENDIS PHARMA A/S (ASND) and COGENT BIOSCIENCES INC (COGT). The fund showed a lot of confidence in some stocks as they added substantially to MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and ENGENE HOLDINGS INC.
The top stock holdings of Cormorant Asset Management, LP are PRAX, , . The fund has invested 12.9% of it's portfolio in PRAXIS PRECISION MEDICINES I and 10.3% of portfolio in BRIDGEBIO ONCOLOGY THERAPEUT.
The fund managers got completely rid off ARCELLX INC (ACLX), CG ONCOLOGY INC and AVIDITY BIOSCIENCES INC (RNA) stocks. They significantly reduced their stock positions in NEWAMSTERDAM PHARMA COMPANY (NAMS), INSMED INC (INSM) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). Cormorant Asset Management, LP opened new stock positions in OLEMA PHARMACEUTICALS INC (OLMA), ASCENDIS PHARMA A/S (ASND) and COGENT BIOSCIENCES INC (COGT). The fund showed a lot of confidence in some stocks as they added substantially to MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and ENGENE HOLDINGS INC.
Cormorant Asset Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cormorant Asset Management, LP made a return of 38.71% in the last quarter. In trailing 12 months, it's portfolio return was 40.04%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| olema pharmaceuticals inc | 68,750,000 |
| ascendis pharma a/s | 21,324,000 |
| cogent biosciences inc | 7,992,000 |
New stocks bought by Cormorant Asset Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| moonlake immunotherapeutics | 118 |
| engene holdings inc | 72.15 |
| alumis inc | 69.3 |
Additions to existing portfolio by Cormorant Asset Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| newamsterdam pharma company | -54.02 |
| insmed inc | -36.05 |
| arcutis biotherapeutics inc | -35.48 |
| gh research plc | -32.17 |
| centessa pharmaceuticals plc | -31.17 |
| abivax sa | -30.77 |
| vaxcyte inc | -28.57 |
| axsome therapeutics inc | -25.00 |
Cormorant Asset Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| biomea fusion inc | -7,213,160 |
| arcellx inc | -63,627,500 |
| cg oncology inc | -25,175,000 |
| korro bio inc | -22,268,800 |
| metsera inc | -20,932,000 |
| avidity biosciences inc | -13,071,000 |
| enliven therapeutics inc | -4,094,000 |
Cormorant Asset Management, LP got rid off the above stocks
Sector Distribution
Cormorant Asset Management, LP has about 52.7% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 52.7 |
| Others | 47.3 |
Market Cap. Distribution
Cormorant Asset Management, LP has about 7.9% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- LARGE-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 47.3 |
| MID-CAP | 26.7 |
| SMALL-CAP | 16.5 |
| LARGE-CAP | 7.9 |
| MICRO-CAP | 1.6 |
Stocks belong to which Index?
About 30.7% of the stocks held by Cormorant Asset Management, LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 69.3 |
| RUSSELL 2000 | 30.7 |
Cormorant Asset Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cormorant Asset Management, LP
Cormorant Asset Management, LP has 32 stocks in it's portfolio. About 60.6% of the portfolio is in top 10 stocks. CRBP proved to be the most loss making stock for the portfolio. PRAX was the most profitable stock for Cormorant Asset Management, LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMLX | amylyx pharmaceuticals inc | 0.22 | 400,000 | 4,832,000 | reduced | -20.00 | ||
| ARQT | arcutis biotherapeutics inc | 0.67 | 500,000 | 14,520,000 | reduced | -35.48 | ||
| ASND | ascendis pharma a/s | 0.99 | 100,000 | 21,324,000 | new | |||
| AXSM | axsome therapeutics inc | 0.63 | 75,000 | 13,698,000 | reduced | -25.00 | ||
| BBIO | bridgebio pharma inc | 4.24 | 1,200,000 | 91,788,000 | reduced | -14.29 | ||
| BMEA | biomea fusion inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CABA | cabaletta bio inc | 0.45 | 4,400,000 | 9,636,000 | reduced | -12.00 | ||
| CNTA | centessa pharmaceuticals plc | 1.53 | 1,325,000 | 33,138,200 | reduced | -31.17 | ||
| COGT | cogent biosciences inc | 0.37 | 225,000 | 7,992,000 | new | |||
| CRBP | corbus pharmaceuticals hldgs | 0.88 | 2,344,970 | 19,088,100 | reduced | -1.26 | ||
| CRNX | crinetics pharmaceuticals in | 0.65 | 300,000 | 13,965,000 | reduced | -25.00 | ||
| DRUG | bright minds biosciences inc | 3.82 | 1,059,330 | 82,670,200 | unchanged | 0.00 | ||
| EWTX | edgewise therapeutics inc | 3.77 | 3,285,000 | 81,517,300 | reduced | -18.08 | ||
| EYPT | eyepoint inc | 6.98 | 8,265,000 | 151,002,000 | reduced | -0.72 | ||
| GHRS | gh research plc | 0.76 | 1,300,000 | 16,510,000 | reduced | -32.17 | ||
| INSM | insmed inc | 2.21 | 275,000 | 47,861,000 | reduced | -36.05 | ||
| JANX | janux therapeutics inc | 0.42 | 650,000 | 8,970,000 | reduced | -23.53 | ||
| MLTX | moonlake immunotherapeutics | 2.65 | 4,355,430 | 57,404,600 | added | 118 | ||
| NAMS | newamsterdam pharma company | 1.62 | 1,000,000 | 35,080,000 | reduced | -54.02 | ||